IDEX Corporation (NYSE: IEX) lifts 2026 outlook after strong Q2 results
Rhea-AI Filing Summary
IDEX Corporation reported strong second-quarter 2026 results, with net sales of $920.6 million, up 6% year over year, and orders of $1,071.6 million, up 29%. Reported diluted EPS rose to $1.93 from $1.74, while adjusted diluted EPS increased 12% to $2.32.
Gross margin improved to 46.3% (46.4% adjusted), and adjusted EBITDA reached $258.3 million with a 28.1% margin. Operating cash flow was $200.0 million and free cash flow $177.0 million, supported by IEEPA tariff refunds. The company repurchased $77 million of stock and paid $54 million in dividends.
Management raised full‑year 2026 guidance, now expecting organic sales growth of 5–6% and adjusted diluted EPS of $8.70–$8.85. The Health & Science Technologies segment led growth, benefiting from AI-driven data center and semiconductor demand.
Positive
- Adjusted diluted EPS grew 12% to $2.32, with net income attributable to IDEX up to $143.4 million and net margin expanding to 15.6%.
- Record orders of $1,071.6 million, a 29% year-over-year increase, supported by elevated demand in AI-driven data center, semiconductor, space and defense markets.
- 2026 outlook raised, with organic sales now projected to grow 5–6% and adjusted diluted EPS guided to $8.70–$8.85, both above prior ranges.
- Strong cash generation with $200.0 million operating cash flow and $177.0 million free cash flow in Q2, resulting in 103% free cash flow conversion.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Net Sales: $920.6 million
Q2 2026 Orders: $1,071.6 million
Q2 2026 Diluted EPS: $1.93
+5 more
8 metrics
Q2 2026 Net Sales
$920.6 million
Three months ended June 30, 2026; increase of $55.2 million or 6% year over year
Q2 2026 Orders
$1,071.6 million
Orders increased $241.8 million, up 29% versus Q2 2025
Q2 2026 Diluted EPS
$1.93
Diluted EPS attributable to IDEX vs $1.74 in the prior-year quarter
Q2 2026 Adjusted Diluted EPS
$2.32
Adjusted diluted EPS attributable to IDEX vs $2.07 in Q2 2025, up 12%
Q2 2026 Operating Cash Flow
$200.0 million
Cash flows from operating activities; 140% of net income in the quarter
Q2 2026 Free Cash Flow
$177.0 million
Free cash flow for the quarter; free cash flow conversion of 103%
2026 Adjusted EPS Guidance
$8.70–$8.85
Full year 2026 adjusted diluted EPS outlook, raised from $8.35–$8.55
2026 Organic Sales Growth Guidance
5–6%
Full year 2026 organic sales projected increase vs prior 3–4% guidance
Key Terms
organic sales, Adjusted EBITDA, IEEPA tariff refunds, free cash flow conversion, +1 more
5 terms
organic sales financial
"Change in organic sales was primarily driven by higher volumes and positive price"
Organic sales are the change in a company’s revenue that comes from its existing business operations, excluding effects of acquisitions, divestitures, and currency swings. Think of it like measuring how much a garden grows from the plants you already tended, rather than adding new pots; investors use organic sales to judge whether demand and core business performance are genuinely improving or if growth is driven by one‑time deals or accounting shifts.
Adjusted EBITDA financial
"Adjusted EBITDA was 258.3 million with an Adjusted EBITDA margin of 28.1%"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
IEEPA tariff refunds regulatory
"Net sales included a reduction from expected customer rebates associated with IEEPA tariff refunds"
Refunds under the International Emergency Economic Powers Act (IEEPA) are repayments of import duties, fees, or penalties that were charged because of trade restrictions or sanctions put in place under emergency authority and later reversed, modified, or found inapplicable. For investors, these refunds can change a company’s past cash outflows and future cost structure—similar to getting a billed charge returned after a rule change—affecting reported earnings or cash available for other uses.
free cash flow conversion financial
"Free cash flow conversion was 103% for the three months ended June 30, 2026"
Free cash flow conversion measures how effectively a company turns its reported profits into actual cash that can be used for growth, debt repayment, or dividends. It compares the cash generated after expenses to the company's net income, similar to how a person might compare their savings to their paycheck. High conversion indicates the company is efficient at translating profits into cash, which is important for investors assessing its financial health and flexibility.
non-GAAP financial measures financial
"These items below are non-GAAP financial measures used to evaluate operating performance"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Earnings Snapshot
Net sales: $920.6 million · Guidance included
Three months ended June 30, 2026
Net sales
$920.6 million
Increased $55.2 million or 6% compared with $865.4 million in Q2 2025
Orders
$1,071.6 million
Increased $241.8 million or 29% compared with $829.8 million in Q2 2025
Diluted EPS
$1.93
Up from $1.74 diluted EPS attributable to IDEX in Q2 2025
Adjusted diluted EPS
$2.32
Up from $2.07 in Q2 2025, a 12% year-over-year increase
Adjusted EBITDA
$258.3 million
Increased $21.1 million from $237.2 million in Q2 2025; margin 28.1%
Guidance
Full year 2026 organic sales projected to increase 5–6% and adjusted diluted EPS to be $8.70–$8.85. Third quarter 2026 organic sales projected to increase 5–7% with adjusted diluted EPS of $2.20–$2.25.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did IDEX (IEX) perform financially in the second quarter of 2026?
IDEX delivered Q2 2026 net sales of $920.6 million, up 6% year over year, and orders of $1,071.6 million, up 29%. Reported diluted EPS was $1.93 and adjusted diluted EPS reached $2.32, a 12% increase from $2.07.
What were the Q2 2026 segment results for IDEX (IEX)?
Health & Science Technologies posted $415.0 million in net sales, up 14% (12% organic). Fluid & Metering Technologies delivered $317.1 million, up 2% (1% organic). Fire & Safety/Diversified Products reported $189.9 million, down 1% both reported and organic.
What full-year and Q3 2026 guidance did IDEX (IEX) provide?
For 2026, IDEX now projects organic sales growth of 5–6% and adjusted diluted EPS of $8.70–$8.85. For Q3 2026, it expects organic sales growth of 5–7% and adjusted diluted EPS of $2.20–$2.25, all on a non-GAAP basis.
How strong were IDEX's (IEX) cash flows and capital returns in Q2 2026?
Operating cash flows were $200.0 million, with free cash flow of $177.0 million and 103% free cash flow conversion. IDEX returned capital via $77 million of share repurchases and $54 million of dividends during the quarter.
How did IEEPA tariff refunds impact IDEX (IEX) Q2 2026 results?
IEEPA tariff effects reduced net sales by $14.7 million but lowered cost of sales by $22.0 million, adding $7.3 million to gross profit. They increased gross margin by 150 bps and benefited adjusted diluted EPS by $0.08 in the quarter.
What are IDEX's (IEX) key non-GAAP earnings measures in Q2 2026?
Key non-GAAP metrics include adjusted net income of $172.4 million, adjusted diluted EPS of $2.32, and adjusted EBITDA of $258.3 million with a 28.1% margin. These exclude restructuring, certain legal items and acquisition-related intangible amortization.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report: July 29, 2026
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
| of incorporation) | Identification No.) | |||||||||||||
(Address of principal executive offices, including zip code)
(847 ) 498-7070
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | ||||||||||||||||||||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||||||||||||||||||||||||||
Item 2.02 – Results of Operations and Financial Condition.
On July 29, 2026, IDEX Corporation (the “Company”) issued a press release announcing financial results for the period ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information contained in this Item 2.02 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 – Financial Statements and Exhibits.
(d) Exhibits
99.1 Press release dated July 29, 2026 announcing IDEX Corporation’s quarterly operating results for the period ended June 30, 2026.
104.0 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IDEX CORPORATION | ||||||||
| By: | /s/ SEAN M. GILLEN | |||||||
| Sean M. Gillen | ||||||||
| Senior Vice President and Chief Financial Officer | ||||||||
| July 29, 2026 | ||||||||
For further information: TRADED: NYSE (IEX) EX-99.1
Investor Contact:
Jim Giannakouros, CFA
Vice President, Investor Relations
(847) 313-9506
IDEX REPORTS SECOND QUARTER RESULTS
Highlights
(All comparisons are against the prior year period unless otherwise noted)
•Record sales of $921 million increased 6% on a reported basis and 5% organically
•Reported diluted EPS of $1.93 increased 11% and record adjusted diluted EPS of $2.32 increased 12%
•Record orders of over $1 billion increased 29% on a reported basis and 28% organically
•Returned capital to shareholders via $77 million of share repurchases and $54 million of dividends
•Raising full year 2026 organic growth and adjusted EPS guidance ranges
NORTHBROOK, IL, July 29, 2026 - IDEX Corporation (NYSE: IEX) today announced its financial results for the three-month period ended June 30, 2026.
“We are very pleased to see continued results momentum as our IDEX teams drove another quarter of strong sales and earnings growth. Orders of over $1 billion in the quarter were a record as we continue to see elevated demand across the advantaged markets where we’ve focused our investments and capabilities,” said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President.
“Our teams executed exceptionally well, as flow-through on strong volume drove earnings above our expectations, demonstrating the benefits of the work already completed to strengthen the quality of our businesses. We continue to advance 8020 initiatives to both fuel higher growth and unlock further margin expansion opportunities across IDEX.”
“We are increasing our full-year financial guidance expectations due to our strong performance year-to-date and improved visibility in the second half of our fiscal year.”
Outlook(1)
•Full year organic sales projected to increase 5% to 6% over the prior year, up from previous guidance of 3% to 4%
•Full year adjusted diluted EPS of $8.70 to $8.85, up approximately 10% year-over-year at midpoint, up from previous guidance of $8.35 to $8.55
•Third quarter 2026 organic sales projected to increase 5% to 7% from the prior year period
•Third quarter 2026 adjusted diluted EPS of $2.20 to $2.25
(1) The Company does not reconcile its forward-looking non-GAAP measures to the most directly comparable U.S. GAAP financial measure because the timing and magnitude of certain items, including future foreign exchange impacts, acquisitions, divestitures, restructuring costs, impairments, tax impacts, and other special items, cannot be reasonably estimated at this time without unreasonable effort. The unavailable information could have a significant impact on GAAP results.
Consolidated Financial Results
| Three Months Ended June 30, | |||||||||||||||||
| (Dollars in millions, except per share amounts) | 2026 | 2025 | Increase (Decrease) | ||||||||||||||
U.S. GAAP Results | |||||||||||||||||
| Orders | $ | 1,071.6 | $ | 829.8 | $ | 241.8 | |||||||||||
Change in reported orders | 29 | % | |||||||||||||||
| Net sales | 920.6 | 865.4 | 55.2 | ||||||||||||||
Change in reported net sales | 6 | % | |||||||||||||||
| Gross profit | 426.8 | 392.2 | 34.6 | ||||||||||||||
| Gross margin | 46.3 | % | 45.3 | % | 100 bps | ||||||||||||
| Net income attributable to IDEX | 143.4 | 131.6 | 11.8 | ||||||||||||||
| Net income margin | 15.6 | % | 15.1 | % | 50 bps | ||||||||||||
| Diluted EPS attributable to IDEX | 1.93 | 1.74 | 0.19 | ||||||||||||||
| Cash flows from operating activities | 200.0 | 161.7 | 38.3 | ||||||||||||||
| Operating cash flow as a percent of net income | 140% | 123% | NM | ||||||||||||||
Non-GAAP Results* | |||||||||||||||||
Change in organic orders | 28 | % | |||||||||||||||
Change in organic sales | 5 | % | |||||||||||||||
| Adjusted gross profit | 427.3 | 392.2 | 35.1 | ||||||||||||||
| Adjusted gross margin | 46.4 | % | 45.3 | % | 110 bps | ||||||||||||
Adjusted net income attributable to IDEX | 172.4 | 156.5 | 15.9 | ||||||||||||||
Adjusted EBITDA | 258.3 | 237.2 | 21.1 | ||||||||||||||
Adjusted EBITDA margin | 28.1 | % | 27.4 | % | 70 bps | ||||||||||||
Adjusted diluted EPS attributable to IDEX | 2.32 | 2.07 | 0.25 | ||||||||||||||
Free cash flow | 177.0 | 146.9 | 30.1 | ||||||||||||||
Free cash flow conversion | 103% | 94% | NM | ||||||||||||||
NM – Not Meaningful | |||||||||||||||||
*Each of these items below are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. | |||||||||||||||||
•Net sales increased primarily as a result of increased organic sales, as well as contributions from acquisitions. The increase in organic sales was primarily driven by higher volumes in our Health & Science Technologies (“HST”) segment and positive price. Net sales included a $14.7 million reduction resulting from expected customer rebates associated with refunds for tariffs under the International Emergency Economic Powers Act (“IEEPA”) that were subsequently invalidated.
•Gross margin and Adjusted gross margin both increased due to net productivity improvements, volume leverage and positive price/cost. Positive price/cost was driven by the net benefit of IEEPA tariff refunds, which contributed 150 basis points to both measures, and more than offset a challenging prior year price/cost comparison. These increases were partially offset by unfavorable mix. Adjusted gross margin excludes restructuring-related charges consisting of accelerated depreciation related to the anticipated closure of a facility in the HST segment.
•Both Diluted EPS and Adjusted diluted EPS increased, primarily due to improved operational results discussed above, including the net impact from IEEPA tariff refunds, which benefited both measures by $0.08.
•Cash flows from operating activities and free cash flow both increased compared to the prior year period, primarily due to cash received for IEEPA tariff refunds of $21.1 million and higher earnings, partially offset by increased working capital, driven by higher sales volumes. The current year period also benefited from lower cash restructuring, income tax and interest payments. These improvements in cash flows from operating activities also benefited free cash flow but were partly offset by higher capital expenditures during the current year period.
Segment Financial Results
Three Months Ended June 30,(1) | |||||||||||||||||
(Dollars in millions) | 2026 | 2025 | Increase (Decrease) | ||||||||||||||
Health & Science Technologies | |||||||||||||||||
| Net sales | $ | 415.0 | $ | 365.3 | $ | 49.7 | |||||||||||
Change in reported net sales | 14 | % | |||||||||||||||
| Change in organic sales* | 12 | % | |||||||||||||||
Adjusted EBITDA(2) | 119.3 | 95.0 | 24.3 | ||||||||||||||
| Adjusted EBITDA margin | 28.7 | % | 26.0 | % | 270 bps | ||||||||||||
Fluid & Metering Technologies | |||||||||||||||||
| Net sales | $ | 317.1 | $ | 310.9 | $ | 6.2 | |||||||||||
Change in reported net sales | 2 | % | |||||||||||||||
| Change in organic sales* | 1 | % | |||||||||||||||
Adjusted EBITDA(2) | 110.3 | 108.7 | 1.6 | ||||||||||||||
| Adjusted EBITDA margin | 34.8 | % | 35.0 | % | (20) bps | ||||||||||||
Fire & Safety/Diversified Products | |||||||||||||||||
| Net sales | $ | 189.9 | $ | 191.5 | $ | (1.6) | |||||||||||
Change in reported net sales | (1 | %) | |||||||||||||||
| Change in organic sales* | (1 | %) | |||||||||||||||
Adjusted EBITDA(2) | 54.9 | 56.4 | (1.5) | ||||||||||||||
| Adjusted EBITDA margin | 28.9 | % | 29.4 | % | (50) bps | ||||||||||||
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. | |||||||||||||||||
(1) Three month data includes the results of the acquisition of Micro-LAM, Inc. (“Micro-LAM”) (July 2025) in the HST segment. | |||||||||||||||||
(2) Segment Adjusted EBITDA excludes unallocated corporate costs which are included in Corporate and other. | |||||||||||||||||
Health & Science Technologies Segment
•Net sales for the second quarter 2026 increased 14%. Organic sales increased 12% driven by higher volumes primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense and positive price. Net sales included a $9.3 million reduction resulting from expected customer rebates associated with IEEPA tariff refunds, which unfavorably impacted organic sales growth by 2%.
•Adjusted EBITDA margin for the second quarter 2026 increased primarily due to volume leverage and positive price/cost. Positive price/cost was driven by the net benefit of 90 basis points from IEEPA tariff refunds.
Fluid & Metering Technologies Segment
•Net sales for the second quarter 2026 increased 2%. Organic sales increased 1% primarily driven by positive price. Net sales included a $3.2 million reduction resulting from expected customer rebates associated with IEEPA tariff refunds, which unfavorably impacted organic sales growth by 2%. Higher volumes in our businesses serving municipal water, semiconductor and mining markets were largely offset by lower volumes in our businesses serving energy, agriculture and chemical markets.
•Adjusted EBITDA margin for the second quarter 2026 decreased primarily due to unfavorable mix, the impacts of which were mostly mitigated by net productivity improvements and positive price/cost. Positive price/cost was driven by the net benefit of 180 basis points from IEEPA tariff refunds, which more than offset a challenging prior year price/cost comparison.
Fire & Safety/Diversified Products Segment
•Both Net sales and organic sales for the second quarter 2026 decreased 1%. Lower volumes within our Fire & Safety businesses driven by lower European rescue demand as well as in our
Dispensing businesses more than offset higher volumes in our BAND-IT business and positive price across the segment. Net sales included a $2.2 million reduction resulting from expected customer rebates associated with IEEPA tariff refunds, which unfavorably impacted organic sales growth by 1%.
•Adjusted EBITDA margin for the second quarter 2026 decreased primarily due to unfavorable mix and volume deleverage, partially offset by other net productivity improvements and positive price/cost. Positive price/cost was driven by the net benefit of 120 basis points from IEEPA tariff refunds, which more than offset a challenging prior year price/cost comparison.
Corporate Costs
Corporate costs included in consolidated Adjusted EBITDA were $26.2 million during the second quarter 2026, up from $22.9 million during the same prior year period primarily driven by higher employee-related costs, including variable compensation.
Other Items
Below is a summary of the impacts of the IEEPA tariff refunds and the related expected customer rebates discussed above:
| Consolidated IDEX | |||||||||||
| (Dollars in millions, except per share amounts) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | |||||||||
| IEEPA Tariff Impacts: | |||||||||||
| Net sales | $ | (14.7) | $ | (14.7) | |||||||
| Organic sales* | (2%) | (1%) | |||||||||
| Cost of sales | $ | (22.0) | $ | (22.0) | |||||||
| Gross profit | $ | 7.3 | $ | 7.3 | |||||||
| Gross margin | 150 bps | 70 bps | |||||||||
| Adjusted gross margin* | 150 bps | 80 bps | |||||||||
| Adjusted EBITDA* | $ | 7.3 | $ | 7.3 | |||||||
| Adjusted EBITDA margin* | 130 bps | 60 bps | |||||||||
| Adjusted diluted EPS attributable to IDEX* | $ | 0.08 | $ | 0.08 | |||||||
| HST | FMT | FSDP | |||||||||||||||
| (Dollars in millions) | Three Months Ended June 30, 2026 | ||||||||||||||||
| IEEPA Tariff Impacts: | |||||||||||||||||
| Net sales | $ | (9.3) | $ | (3.2) | $ | (2.2) | |||||||||||
| Organic sales* | (2%) | (2%) | (1%) | ||||||||||||||
| Cost of sales | $ | (10.5) | $ | (7.7) | $ | (3.8) | |||||||||||
| Adjusted EBITDA | $ | 1.2 | $ | 4.5 | $ | 1.6 | |||||||||||
| Adjusted EBITDA margin | 90 bps | 180 bps | 120 bps | ||||||||||||||
| Six Months Ended June 30, 2026 | |||||||||||||||||
| IEEPA Tariff Impacts: | |||||||||||||||||
| Net sales | $ | (9.3) | $ | (3.2) | $ | (2.2) | |||||||||||
| Organic sales* | (2%) | —% | (1%) | ||||||||||||||
| Cost of sales | $ | (10.5) | $ | (7.7) | $ | (3.8) | |||||||||||
| Adjusted EBITDA | $ | 1.2 | $ | 4.5 | $ | 1.6 | |||||||||||
| Adjusted EBITDA margin | 50 bps | 90 bps | 60 bps | ||||||||||||||
| *Each of these items are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. | |||||||||||||||||
Conference Call
IDEX will host its second quarter earnings conference call on Wednesday, July 29, 2026 at 8:00 a.m. CT. The call will be an audio webcast and accessible on the Company's Investor Relations site at https://investors.idexcorp.com. Associated earnings presentation materials will be available on the Company's website prior to the call.
Interested parties can access the conference by dialing 833.461.5787 and using confirmation code 212572551. Please connect five minutes prior to the start of the conference call.
A replay of the earnings call and associated earnings presentation materials will be available on the Company’s website after the call.
Forward-Looking Statements
This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company’s third quarter 2026 and full year 2026 outlook including expected organic sales and expected adjusted earnings per share and the assumptions underlying these expectations, capital return strategy, anticipated future acquisition behavior and the anticipated benefits and performance of the Company’s recent or future acquisitions, resource and capital deployment and focus and organic and inorganic growth, the Company’s ability to adapt to macroeconomic challenges, anticipated impacts of tariffs and global trade policies and changes in law, anticipated trends in end markets, including expectations regarding future order volumes and order patterns, anticipated growth initiatives and expansions and execution of those growth initiatives and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “likely to be,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release.
The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks, wars and global conflicts; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the continued growth of artificial intelligence (“AI”) and any related changes to demand in AI-driven markets served by the Company’s customers; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.
Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the United States Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.
About IDEX
IDEX Corporation (NYSE: IEX), a global engineered products company, is comprised of three primary business segments – Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety/Diversified Products. Thousands of IDEX employees around the world design and manufacture highly engineered components and applied solutions that are vital to the advances of modern life and help IDEX live its purpose – Trusted Solutions, Improving Lives™. From satellite communications to water systems, from medical diagnostic components to emergency rescue tools and more, we collaborate with customers in the most critical industries to develop solutions that make the world better today and into the future. Founded in 1988, IDEX now includes more than 50 dynamic businesses around the world and manufacturing operations in more than 20 countries.
For further information on IDEX Corporation and its business units, visit the Company’s website at www.idexcorp.com.
(Financial reports follow)
IDEX CORPORATION
Condensed Consolidated Statements of Income
(in millions, except per share amounts)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net sales | $ | 920.6 | $ | 865.4 | $ | 1,807.5 | $ | 1,679.7 | |||||||||||||||
| Cost of sales | 493.8 | 473.2 | 982.6 | 918.6 | |||||||||||||||||||
| Gross profit | 426.8 | 392.2 | 824.9 | 761.1 | |||||||||||||||||||
| Selling, general and administrative expenses | 224.1 | 203.6 | 442.4 | 413.0 | |||||||||||||||||||
| Restructuring expenses and asset impairments | 2.8 | 0.7 | 10.2 | 18.2 | |||||||||||||||||||
| Operating income | 199.9 | 187.9 | 372.3 | 329.9 | |||||||||||||||||||
| Other (income) expense – net | (1.3) | 2.4 | (1.9) | 3.8 | |||||||||||||||||||
Interest expense – net | 15.1 | 15.6 | 31.1 | 31.7 | |||||||||||||||||||
| Income before income taxes | 186.1 | 169.9 | 343.1 | 294.4 | |||||||||||||||||||
| Provision for income taxes | 42.7 | 38.8 | 79.8 | 67.9 | |||||||||||||||||||
| Net income | 143.4 | 131.1 | 263.3 | 226.5 | |||||||||||||||||||
| Net loss attributable to noncontrolling interest | — | 0.5 | 0.1 | 0.6 | |||||||||||||||||||
| Net income attributable to IDEX | $ | 143.4 | $ | 131.6 | $ | 263.4 | $ | 227.1 | |||||||||||||||
| Earnings per Common Share: | |||||||||||||||||||||||
| Basic earnings per common share attributable to IDEX | $ | 1.94 | $ | 1.74 | $ | 3.55 | $ | 3.00 | |||||||||||||||
| Diluted earnings per common share attributable to IDEX | $ | 1.93 | $ | 1.74 | $ | 3.54 | $ | 3.00 | |||||||||||||||
| Share Data: | |||||||||||||||||||||||
| Basic weighted average common shares outstanding | 74.0 | 75.5 | 74.2 | 75.6 | |||||||||||||||||||
| Diluted weighted average common shares outstanding | 74.2 | 75.5 | 74.3 | 75.7 | |||||||||||||||||||
IDEX CORPORATION
Condensed Consolidated Balance Sheets
(in millions)
(unaudited)
| June 30, 2026 | December 31, 2025 | ||||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 621.3 | $ | 580.0 | |||||||
Receivables – net | 547.8 | 521.7 | |||||||||
Inventories – net | 520.3 | 479.4 | |||||||||
| Other current assets | 83.9 | 62.1 | |||||||||
| Total current assets | 1,773.3 | 1,643.2 | |||||||||
| Property, plant and equipment – net | 463.6 | 468.0 | |||||||||
| Goodwill | 3,382.6 | 3,414.5 | |||||||||
| Intangible assets - net | 1,164.5 | 1,247.4 | |||||||||
| Other noncurrent assets | 146.0 | 153.9 | |||||||||
| Total assets | $ | 6,930.0 | $ | 6,927.0 | |||||||
| Liabilities and equity | |||||||||||
| Current liabilities | |||||||||||
| Trade accounts payable | $ | 233.7 | $ | 224.7 | |||||||
| Accrued expenses | 293.5 | 297.0 | |||||||||
| Current portion of long-term borrowings | 0.4 | 0.7 | |||||||||
| Dividends payable | 54.0 | 53.0 | |||||||||
| Total current liabilities | 581.6 | 575.4 | |||||||||
Long-term borrowings – net | 1,858.5 | 1,820.1 | |||||||||
| Deferred income taxes | 297.8 | 303.0 | |||||||||
| Other noncurrent liabilities | 185.5 | 202.3 | |||||||||
| Total liabilities | 2,923.4 | 2,900.8 | |||||||||
| Shareholders' equity | |||||||||||
| Preferred stock | — | — | |||||||||
| Common stock | 0.9 | 0.9 | |||||||||
| Treasury stock | (1,525.1) | (1,423.2) | |||||||||
| Additional paid-in capital | 875.2 | 892.1 | |||||||||
| Retained earnings | 4,655.4 | 4,500.1 | |||||||||
| Accumulated other comprehensive income | 1.6 | 57.6 | |||||||||
| Total shareholders' equity | 4,008.0 | 4,027.5 | |||||||||
| Noncontrolling interest | (1.4) | (1.3) | |||||||||
| Total equity | 4,006.6 | 4,026.2 | |||||||||
| Total liabilities and equity | $ | 6,930.0 | $ | 6,927.0 | |||||||
IDEX CORPORATION
Condensed Consolidated Statements of Cash Flows
(in millions)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Cash flows from operating activities | |||||||||||||||||||||||
| Net income | $ | 143.4 | $ | 131.1 | $ | 263.3 | $ | 226.5 | |||||||||||||||
| Adjustments to reconcile net income to net cash flows provided by operating activities: | |||||||||||||||||||||||
Asset impairments | — | 0.6 | 4.8 | 0.6 | |||||||||||||||||||
| Depreciation | 20.2 | 19.0 | 40.1 | 37.4 | |||||||||||||||||||
| Amortization of intangible assets | 33.2 | 32.0 | 67.0 | 63.5 | |||||||||||||||||||
| Share-based compensation expense | 6.1 | 5.2 | 21.9 | 18.8 | |||||||||||||||||||
| Deferred income taxes | (0.7) | 0.7 | (1.3) | 1.6 | |||||||||||||||||||
Changes in (net of the effect from acquisitions/divestitures and foreign currency translation): | |||||||||||||||||||||||
Receivables – net | 4.7 | 13.9 | (30.7) | 1.6 | |||||||||||||||||||
Inventories – net | (20.2) | (10.7) | (45.7) | (45.6) | |||||||||||||||||||
| Other current assets | (6.3) | (14.8) | (21.4) | (21.8) | |||||||||||||||||||
| Trade accounts payable | 8.6 | (10.3) | 9.2 | (0.7) | |||||||||||||||||||
| Deferred revenue | (1.5) | (2.4) | 2.7 | 6.4 | |||||||||||||||||||
| Accrued expenses | 10.8 | (4.5) | (8.0) | (22.4) | |||||||||||||||||||
Other – net | 1.7 | 1.9 | 1.8 | 1.5 | |||||||||||||||||||
| Net cash flows provided by operating activities | 200.0 | 161.7 | 303.7 | 267.4 | |||||||||||||||||||
| Cash flows from investing activities | |||||||||||||||||||||||
| Capital expenditures | (23.0) | (14.8) | (40.7) | (29.1) | |||||||||||||||||||
| Acquisition of business, net of cash acquired | — | — | — | 4.2 | |||||||||||||||||||
Other – net | 0.7 | 0.3 | (2.0) | 0.4 | |||||||||||||||||||
| Net cash flows used in investing activities | (22.3) | (14.5) | (42.7) | (24.5) | |||||||||||||||||||
| Cash flows from financing activities | |||||||||||||||||||||||
Borrowings under revolving credit facilities | 105.0 | 50.0 | 205.0 | 50.0 | |||||||||||||||||||
| Payments under revolving credit facilities | (118.0) | (62.5) | (163.3) | (92.7) | |||||||||||||||||||
| Payment of long-term borrowings | — | (100.0) | — | (100.0) | |||||||||||||||||||
| Cash dividends paid to shareholders | (53.9) | (53.5) | (106.7) | (105.9) | |||||||||||||||||||
Proceeds (payments) from share issuances, net of shares withheld for taxes | 4.8 | 0.3 | 10.6 | (0.2) | |||||||||||||||||||
| Repurchases of common stock | (77.1) | (50.0) | (153.4) | (100.0) | |||||||||||||||||||
Other – net | (0.1) | (0.2) | (0.3) | (0.4) | |||||||||||||||||||
| Net cash flows used in financing activities | (139.3) | (215.9) | (208.1) | (349.2) | |||||||||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | (2.1) | 26.5 | (10.7) | 37.4 | |||||||||||||||||||
| Net increase (decrease) in cash and cash equivalents and restricted cash | 36.3 | (42.2) | 42.2 | (68.9) | |||||||||||||||||||
| Cash and cash equivalents and restricted cash at beginning of period | 591.8 | 612.2 | 585.9 | 638.9 | |||||||||||||||||||
| Cash and cash equivalents and restricted cash at end of period | $ | 628.1 | $ | 570.0 | $ | 628.1 | $ | 570.0 | |||||||||||||||
IDEX CORPORATION
Company and Segment Financial Information
(in millions)
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Net sales | |||||||||||||||||||||||
| Health & Science Technologies | $ | 415.0 | $ | 365.3 | $ | 813.4 | $ | 706.8 | |||||||||||||||
| Fluid & Metering Technologies | 317.1 | 310.9 | 618.6 | 601.4 | |||||||||||||||||||
| Fire & Safety/Diversified Products | 189.9 | 191.5 | 378.2 | 375.8 | |||||||||||||||||||
| Eliminations | (1.4) | (2.3) | (2.7) | (4.3) | |||||||||||||||||||
| Total IDEX | $ | 920.6 | $ | 865.4 | $ | 1,807.5 | $ | 1,679.7 | |||||||||||||||
| Depreciation | |||||||||||||||||||||||
| Health & Science Technologies | $ | 12.9 | $ | 11.9 | $ | 25.4 | $ | 23.6 | |||||||||||||||
| Fluid & Metering Technologies | 4.8 | 4.4 | 9.7 | 8.8 | |||||||||||||||||||
| Fire & Safety/Diversified Products | 2.4 | 2.4 | 4.8 | 4.6 | |||||||||||||||||||
| Corporate Office | 0.1 | 0.3 | 0.2 | 0.4 | |||||||||||||||||||
| Total IDEX | $ | 20.2 | $ | 19.0 | $ | 40.1 | $ | 37.4 | |||||||||||||||
| Amortization of intangible assets | |||||||||||||||||||||||
| Health & Science Technologies | $ | 26.8 | $ | 25.4 | $ | 53.9 | $ | 50.0 | |||||||||||||||
| Fluid & Metering Technologies | 5.2 | 5.4 | 10.6 | 10.7 | |||||||||||||||||||
| Fire & Safety/Diversified Products | 1.2 | 1.2 | 2.5 | 2.8 | |||||||||||||||||||
| Total IDEX | $ | 33.2 | $ | 32.0 | $ | 67.0 | $ | 63.5 | |||||||||||||||
| Restructuring expenses and asset impairments | |||||||||||||||||||||||
| Health & Science Technologies | $ | 2.2 | $ | 0.7 | $ | 3.3 | $ | 12.1 | |||||||||||||||
| Fluid & Metering Technologies | 0.4 | — | 5.5 | 4.2 | |||||||||||||||||||
| Fire & Safety/Diversified Products | 0.2 | — | 0.5 | 1.6 | |||||||||||||||||||
| Corporate Office | — | — | 0.9 | 0.3 | |||||||||||||||||||
| Total IDEX | $ | 2.8 | $ | 0.7 | $ | 10.2 | $ | 18.2 | |||||||||||||||
Non-GAAP Measures of Financial Performance
The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). To supplement its U.S. GAAP financial results, the Company presents certain non-GAAP financial measures. Management uses these non-GAAP measures to evaluate operating performance, assess trends, allocate resources and support financial and operational decision-making. Management believes these measures provide investors with additional insight into the Company’s ongoing business performance and enhance comparability across reporting periods by excluding the impact of items that management does not consider reflective of ongoing operations.
Management uses Adjusted EBITDA as its measure of segment performance. Management believes it is a useful indicator of the strength and performance of the Company and its segments’ ongoing business operations as well as a way for investors to evaluate and compare operating performance and value companies within the Company’s industry. Management believes that Adjusted EBITDA margin is useful for the same reason as Adjusted EBITDA. The definition of Adjusted EBITDA used here may differ from that used by other companies.
The Company defines its non-GAAP measures below and presents reconciliations of these non-GAAP measures to their most directly comparable U.S. GAAP measures in the tables that follow. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.
•Organic orders and organic sales are calculated as orders and Net sales excluding amounts from acquired or divested businesses during the first twelve months of ownership or prior to divestiture and excluding the impact of foreign currency translation.
•Adjusted gross profit is calculated as Gross profit, adjusted to exclude the impact of fair value inventory step-up charges and restructuring-related charges.
•Adjusted gross margin is calculated as Adjusted gross profit divided by Net sales.
•Adjusted net income attributable to IDEX is calculated as Net income attributable to IDEX, adjusted to exclude the impact of Restructuring expenses and asset impairments and other restructuring-related charges, acquisition-related intangible asset amortization and legal settlements and contingencies, all net of the statutory tax expense or benefit.
•Adjusted diluted EPS attributable to IDEX is calculated as Adjusted net income attributable to IDEX divided by the diluted weighted average shares outstanding.
•Consolidated Adjusted EBITDA is calculated as consolidated earnings before interest expense - net, income taxes, depreciation and amortization, or consolidated EBITDA, adjusted to exclude the impact of Restructuring expenses and asset impairments and other restructuring-related charges and legal settlements and contingencies.
•Consolidated Adjusted EBITDA margin is calculated as Consolidated Adjusted EBITDA divided by Net sales.
•Free cash flow is calculated as cash flows from operating activities less capital expenditures. Free cash flow conversion is calculated as free cash flow divided by Adjusted net income attributable to IDEX.
These non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from those results should be carefully evaluated. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely.
Table 1: Reconciliations of the Change in Net Sales to Change in Organic Sales
| HST | FMT | FSDP | IDEX | ||||||||||||||||||||
| Three Months Ended June 30, 2026 | |||||||||||||||||||||||
| Change in net sales | 14 | % | 2 | % | (1 | %) | 6 | % | |||||||||||||||
| Less: | |||||||||||||||||||||||
Net impact from acquisitions/divestitures(1) | 2 | % | — | % | — | % | 1 | % | |||||||||||||||
Impact from foreign currency(2) | — | % | 1 | % | — | % | — | % | |||||||||||||||
| Change in organic sales | 12 | % | 1 | % | (1 | %) | 5 | % | |||||||||||||||
| Six Months Ended June 30, 2026 | |||||||||||||||||||||||
| Change in net sales | 15 | % | 3 | % | 1 | % | 8 | % | |||||||||||||||
| Less: | |||||||||||||||||||||||
Net impact from acquisitions/divestitures(1) | 2 | % | — | % | — | % | 1 | % | |||||||||||||||
Impact from foreign currency(2) | 2 | % | 1 | % | 2 | % | 2 | % | |||||||||||||||
| Change in organic sales | 11 | % | 2 | % | (1 | %) | 5 | % | |||||||||||||||
(1) Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.
(2) The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.
Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (dollars in millions)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Gross profit | $ | 426.8 | $ | 392.2 | $ | 824.9 | $ | 761.1 | |||||||||||||||
Restructuring-related charges(1) | 0.5 | — | 0.5 | — | |||||||||||||||||||
| Adjusted gross profit | $ | 427.3 | $ | 392.2 | $ | 825.4 | $ | 761.1 | |||||||||||||||
| Net sales | $ | 920.6 | $ | 865.4 | $ | 1,807.5 | $ | 1,679.7 | |||||||||||||||
| Gross margin | 46.3 | % | 45.3 | % | 45.6 | % | 45.3 | % | |||||||||||||||
| Adjusted gross margin | 46.4 | % | 45.3 | % | 45.7 | % | 45.3 | % | |||||||||||||||
(1) Restructuring-related charges represent accelerated depreciation related to the anticipated closure of a facility in the HST segment.
Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Reported net income attributable to IDEX | $ | 143.4 | $ | 131.6 | $ | 263.4 | $ | 227.1 | ||||||||||||||||||
Restructuring expenses and asset impairments and other restructuring-related charges(1) | 3.3 | 0.4 | 10.7 | 17.9 | ||||||||||||||||||||||
| Tax impact on restructuring expenses and asset impairments and other restructuring-related charges | (0.8) | (0.2) | (2.5) | (4.3) | ||||||||||||||||||||||
Legal settlements and contingencies(2) | 0.9 | — | (2.8) | — | ||||||||||||||||||||||
| Tax impact on legal settlements and contingencies | 0.3 | — | 1.1 | — | ||||||||||||||||||||||
| Acquisition-related intangible asset amortization | 33.2 | 32.0 | 67.0 | 63.5 | ||||||||||||||||||||||
| Tax impact on acquisition-related intangible asset amortization | (7.9) | (7.3) | (15.9) | (14.7) | ||||||||||||||||||||||
| Adjusted net income attributable to IDEX | $ | 172.4 | $ | 156.5 | $ | 321.0 | $ | 289.5 | ||||||||||||||||||
| Reported diluted EPS attributable to IDEX | $ | 1.93 | $ | 1.74 | $ | 3.54 | $ | 3.00 | ||||||||||||||||||
Restructuring expenses and asset impairments and other restructuring-related charges(1) | 0.05 | 0.01 | 0.15 | 0.24 | ||||||||||||||||||||||
| Tax impact on restructuring expenses and asset impairments and other restructuring-related charges | (0.01) | — | (0.03) | (0.06) | ||||||||||||||||||||||
Legal settlements and contingencies(2) | 0.01 | — | (0.04) | — | ||||||||||||||||||||||
| Tax impact on legal settlements and contingencies | — | — | 0.01 | — | ||||||||||||||||||||||
| Acquisition-related intangible asset amortization | 0.45 | 0.42 | 0.90 | 0.83 | ||||||||||||||||||||||
| Tax impact on acquisition-related intangible asset amortization | (0.11) | (0.10) | (0.21) | (0.19) | ||||||||||||||||||||||
| Adjusted diluted EPS attributable to IDEX | $ | 2.32 | $ | 2.07 | $ | 4.32 | $ | 3.82 | ||||||||||||||||||
| Diluted weighted average shares outstanding | 74.2 | 75.5 | 74.3 | 75.7 | ||||||||||||||||||||||
(1) Restructuring expenses and asset impairments and other restructuring-related charges consist of the following:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Restructuring expenses and asset impairments | $ | 2.8 | $ | 0.7 | $ | 10.2 | $ | 18.2 | |||||||||||||||
Less: Restructuring expenses and asset impairments attributable to noncontrolling interest(a) | — | (0.3) | — | (0.3) | |||||||||||||||||||
Other restructuring-related charges(b) | 0.5 | — | 0.5 | — | |||||||||||||||||||
| Restructuring expenses and asset impairments and other restructuring-related charges | $ | 3.3 | $ | 0.4 | $ | 10.7 | $ | 17.9 | |||||||||||||||
(a) Restructuring expenses and asset impairments recorded during the three and six months ended June 30, 2025, respectively, included charges of $0.6 million recognized by the Company’s joint venture, $0.3 million of which was attributable to noncontrolling interest.
(b) Other restructuring-related charges represent accelerated depreciation related to the anticipated closure of a facility in the HST segment.
(2) Legal settlements and contingencies represent settlement funds received in excess of legal costs incurred related to a patent infringement lawsuit within the Fluid & Meting Technologies (“FMT”) segment and a class action lawsuit at Corporate, net of estimated settlement costs related to certain legal matters within the HST segment.
Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Reported net income | $ | 143.4 | $ | 131.1 | $ | 263.3 | $ | 226.5 | |||||||||||||||
| Provision for income taxes | 42.7 | 38.8 | 79.8 | 67.9 | |||||||||||||||||||
| Interest expense - net | 15.1 | 15.6 | 31.1 | 31.7 | |||||||||||||||||||
Depreciation(1) | 20.2 | 19.0 | 40.1 | 37.4 | |||||||||||||||||||
| Amortization | 33.2 | 32.0 | 67.0 | 63.5 | |||||||||||||||||||
| Restructuring expenses and asset impairments | 2.8 | 0.7 | 10.2 | 18.2 | |||||||||||||||||||
Legal settlements and contingencies(2) | 0.9 | — | (2.8) | — | |||||||||||||||||||
| Adjusted EBITDA | $ | 258.3 | $ | 237.2 | $ | 488.7 | $ | 445.2 | |||||||||||||||
| Adjusted EBITDA Components | |||||||||||||||||||||||
| HST | $ | 119.3 | $ | 95.0 | $ | 225.3 | $ | 182.4 | |||||||||||||||
| FMT | 110.3 | 108.7 | 209.0 | 204.0 | |||||||||||||||||||
| FSDP | 54.9 | 56.4 | 110.7 | 110.6 | |||||||||||||||||||
| Corporate and other | (26.2) | (22.9) | (56.3) | (51.8) | |||||||||||||||||||
| Total Adjusted EBITDA | $ | 258.3 | $ | 237.2 | $ | 488.7 | $ | 445.2 | |||||||||||||||
| Net sales | $ | 920.6 | $ | 865.4 | $ | 1,807.5 | $ | 1,679.7 | |||||||||||||||
| Net income margin | 15.6 | % | 15.1 | % | 14.6 | % | 13.5 | % | |||||||||||||||
| Adjusted EBITDA margin | 28.1 | % | 27.4 | % | 27.0 | % | 26.5 | % | |||||||||||||||
(1) Depreciation includes accelerated depreciation related to the anticipated closure of a facility in the HST segment, which was included in Restructuring-related charges in Table 2 and in Restructuring expenses and asset impairments and other restructuring-related charges in Table 3 above.
(2) Legal settlements and contingencies represent settlement funds received in excess of legal costs incurred related to a patent infringement lawsuit within the FMT segment and a class action lawsuit at Corporate, net of estimated settlement costs related to certain legal matters within the HST segment.
Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Cash flows from operating activities | $ | 200.0 | $ | 161.7 | $ | 303.7 | $ | 267.4 | |||||||||||||||
| Less: Capital expenditures | 23.0 | 14.8 | 40.7 | 29.1 | |||||||||||||||||||
| Free cash flow | $ | 177.0 | $ | 146.9 | $ | 263.0 | $ | 238.3 | |||||||||||||||
| Reported net income attributable to IDEX | $ | 143.4 | $ | 131.6 | $ | 263.4 | $ | 227.1 | |||||||||||||||
| Adjusted net income attributable to IDEX | 172.4 | 156.5 | 321.0 | 289.5 | |||||||||||||||||||
| Operating cash flow as a percent of net income | 140 | % | 123 | % | 115 | % | 118 | % | |||||||||||||||
| Free cash flow conversion | 103 | % | 94 | % | 82 | % | 82 | % | |||||||||||||||